Mersana Therapeutics' core business segment revolves around the research, development, and clinical advancement of antibody-drug conjugates (ADCs). This involves leveraging proprietary platforms like Dolasynthen and immunosynthen to create novel ADC candidates. The company focuses on identifying and validating promising cancer targets, engineering antibodies with high affinity and specificity, and conjugating them with potent cytotoxic payloads. R&D activities include preclinical studies, IND-enabling studies, and Phase 1/2 clinical trials. The therapeutic areas of focus include ovarian cancer, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Mersana aims to improve patient outcomes by delivering targeted therapies that selectively kill cancer cells while minimizing off-target toxicities. Strategic partnerships with companies like Merck KGaA and GSK are crucial for expanding the ADC pipeline and accelerating drug development.